AMENDMENT TO AGREEMENT AND PLAN OF MERGER
This Amendment (the “ Amendment ”), dated as of October 15, 2008, amends that certain Agreement and
Plan of Merger (the “ Merger Agreement ”) by and among Coria Laboratories, Ltd., a Delaware corporation
(the “ Company ”), its stockholders (i) DFB Pharmaceuticals, Inc., a Texas corporation, (ii) H. Paul Dorman,
(iii) John W. Feik, (iv) Anne Burnett Windfohr, (v) John L. Marion and (vi) John W. Mason (collectively, the “
Sellers ”), Valeant Pharmaceuticals International, a Delaware corporation (“ Buyer ”), and CL Acquisition Corp.,
a Delaware corporation and wholly-owned subsidiary of Buyer (“ Newco ”). All capitalized terms used in this
Amendment but not otherwise defined herein shall have the respective meanings ascribed to such terms in the
WHEREAS, pursuant to Section 12.4 of the Merger Agreement, the parties to the Merger Agreement desire
that the Merger Agreement be amended.
NOW, THEREFORE, in consideration of the foregoing and the promises and covenants contained herein,
and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and
intending to be legally bound hereby, the undersigned hereby agree as follows:
1. Amendment .
A. Until such time as the parties shall negotiate and execute an Amended and Restated Facility Lease, the
term “Amended and Restated Facility Lease” as used throughout the Merger Agreement shall mean that certain
Lease Term Sheet, dated October 15, 2008, by and between the Company and Healthpoint, Ltd.
B. Section 9.8 of the Merger Agreement is hereby deleted in its entirety and replaced with the following:
2. Consent to Assignment . The parties hereto agree that the Successor Corporations may assign to Valeant
Pharmaceuticals North America, or any of its other affiliates, any and all of its rights under the Transaction
3. Governing Law . Th